share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K：外國發行人報告
美股SEC公告 ·  08/26 18:17

牛牛AI助理已提取核心訊息

SciSparc Ltd., a clinical-stage pharmaceutical company, announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase IIb clinical trial of SCI-110, aimed at treating Tourette Syndrome (TS). The trial is set to take place at three renowned institutions: Yale Child Study Center at Yale School of Medicine in the USA, Hannover Medical School in Germany, and Tel Aviv Sourasky Medical Center in Israel. Institutional Review Board approvals have been obtained from all sites, along with necessary approvals from the Israeli Ministry of Health and the Federal Institute for Drugs and Medical Devices in Germany. The trial will assess the efficacy, safety, and tolerability of SCI-110 in adults aged 18 to 65, comparing the drug to a placebo using the Yale Global Tic Severity Scale. SciSparc's CEO, Oz Adler, expressed confidence in SCI-110's potential to change the treatment landscape for TS. The company also has other drug development programs based on cannabinoid pharmaceuticals for various conditions.
SciSparc Ltd., a clinical-stage pharmaceutical company, announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase IIb clinical trial of SCI-110, aimed at treating Tourette Syndrome (TS). The trial is set to take place at three renowned institutions: Yale Child Study Center at Yale School of Medicine in the USA, Hannover Medical School in Germany, and Tel Aviv Sourasky Medical Center in Israel. Institutional Review Board approvals have been obtained from all sites, along with necessary approvals from the Israeli Ministry of Health and the Federal Institute for Drugs and Medical Devices in Germany. The trial will assess the efficacy, safety, and tolerability of SCI-110 in adults aged 18 to 65, comparing the drug to a placebo using the Yale Global Tic Severity Scale. SciSparc's CEO, Oz Adler, expressed confidence in SCI-110's potential to change the treatment landscape for TS. The company also has other drug development programs based on cannabinoid pharmaceuticals for various conditions.
SciSparc Ltd.，一家臨床階段的藥品公司，宣佈向美國食品和藥物管理局（FDA）提交了SCI-110的Ⅱb期臨床試驗的新藥（IND）申請，旨在治療抽動症（TS）。 該試驗計劃在三家知名機構進行：美國耶魯醫學院的耶魯兒童研究中心，德國的漢諾威醫學院以及以色列的特拉維夫索拉斯基醫療中心。所有場所都已獲得機構審查委員會的批准，以及以色列衛生部和德國聯邦藥品和醫療器械所必要的批准。 該試驗將評估18至65歲成年人SCI-110的療效、安全性和耐受性，將該藥物與安慰劑使用耶魯全球抽動症狀嚴重性量表進行比較。SciSparc的首席執行官Oz Adler對SCI-110改變TS治療格局的潛力表示信心。該公司還擁有其他基於大麻素藥品的藥物開發計劃，用於治療各種病症。
SciSparc Ltd.，一家臨床階段的藥品公司，宣佈向美國食品和藥物管理局（FDA）提交了SCI-110的Ⅱb期臨床試驗的新藥（IND）申請，旨在治療抽動症（TS）。 該試驗計劃在三家知名機構進行：美國耶魯醫學院的耶魯兒童研究中心，德國的漢諾威醫學院以及以色列的特拉維夫索拉斯基醫療中心。所有場所都已獲得機構審查委員會的批准，以及以色列衛生部和德國聯邦藥品和醫療器械所必要的批准。 該試驗將評估18至65歲成年人SCI-110的療效、安全性和耐受性，將該藥物與安慰劑使用耶魯全球抽動症狀嚴重性量表進行比較。SciSparc的首席執行官Oz Adler對SCI-110改變TS治療格局的潛力表示信心。該公司還擁有其他基於大麻素藥品的藥物開發計劃，用於治療各種病症。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間